A Phase 1, Open-label Study to Assess Safety, Biodistribution, and Internal Radiation Dosimetry of rhPSMA-7.3 (18F) Injection in Healthy Volunteers, and to Assess Safety and Investigate the Imaging Characteristics in Subjects With Prostate Cancer
Latest Information Update: 19 May 2020
At a glance
- Drugs Fluorine 18 flotufolastat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
Most Recent Events
- 15 May 2020 Status changed from recruiting to completed.
- 15 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Apr 2020.
- 15 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2019.